Table 5.
Clinical features and outcomes in acute promyelocytic leukemia (APL) patients with CD56 expression, as reported in published works
| Authors | No. of patients | Treatment | CD56+ APL (%) | Clinical features in patients with CD56+ APL* | CR rate |
CIR |
CIR (extramedullary) |
DFS† |
OS |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD56+ | CD56− | CD56+ | CD56− | CD56+ | CD56− | CD56+ | CD56− | CD56+ | CD56− | |||||
| Murray et al.9 | 50 | CT alone / ATRA alone / ATRA + CT | 24% | S-isoform↑, Fibrinogen↓ | 50%* | 84% | NA | NA | NA | NA | NA | NA | 5 weeks* | 232 weeks |
| Ferrara et al.10 | 100 | ATRA + CT | 15% | No effect | 87% | 94% | NA | NA | 13% | 8% | 22 months | NR | 62%* | 86% |
| Ito et al.11 | 28 | ATRA + CT | 14% | Coexpression of CD34 | 100% | 87% | NA | NA | 75%* | 0% | 4 months* | NR | 26 months | NR |
| Montesinos et al.12 | 651 | CT alone / ATRA + CT | 11% | Initial WBC counts↑, Albumin↓, S-isoform↑, Coexpression of CD2, CD7, CD15, CD34, CD117, and HLA-DR | 85% | 92% | 22%* | 10% | 7%* | 1% | 73%* | 85% | 78% | 84% |
| Present study (all patients) | 225 | ATRA + CT | 10% | Initial platelet counts↓, Severe DIC↑, Coexpression of CD2, CD7, CD34, and HLA-DR | 91% | 95% | 39% | 24% | 5% | 1.5% | 48% | 65% | 74% | 79% |
| Present study (initial WBC counts ≥3.0 × 109/L) | 112 | ATRA + CT | 12% | 92% | 94% | 54%* | 29% | 9.3% | 1.1% | 31%* | 64% | 62% | 79% | |
*
Significant difference.
†
Event-free survival in present study. APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; CIR, cumulative incidence of relapse; CR, complete remission; CT, chemotherapy; DFS, disease-free survival; DIC, disseminated intravascular coagulation; HLA, human leukocyte antigen; NA, not available; NR, not reached; OS, overall survival; WBC, white blood cell.